F-1/A: Charming Medical Limited Files for U.S. IPO to Fund Expansion Amidst Going Concern Doubts and Hong Kong Regulatory Uncertainties

Charming Medical Limited, a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired beauty and wellness services, is seeking to raise up to $8 million in a U.S. initial public offering to fuel its expansion and strategic investments, despite its auditor raising substantial doubt about its ability to continue as a going concern.

Summary

• Charming Medical Limited is a British Virgin Islands holding company that operates TCM-inspired beauty, wellness, and postpartum services and products in Hong Kong through its four operating subsidiaries under the 'Beauty Lab Group' brand.
• The company generated total revenue of $6,015,375 for the fiscal year ended March 31, 2024, a 70.4% increase from $3,530,822 in FY2023.
• Net income for FY2024 was $821,743, a significant improvement from a net loss of $335,605 in FY2023.
• For the six months ended September 30, 2024, total revenue was $2,958,508, up 12.0% from $2,641,503 in the same period of 2023, with net income of $468,817 compared to $377,651.
• The company plans to offer 1,600,000 Class A Ordinary Shares in its IPO, with an anticipated price range of US$4.00 to US$6.00 per share, aiming for approximately $6.6 million in net proceeds.
• Proceeds from the IPO are allocated as: 40% for business and geographic expansion (e.g., Southeast Asia), 30% for strategic investment and acquisitions, 10% for research and development, and 20% for general working capital and corporate purposes.
• The company had a working capital deficit of $2,281,970 as of September 30, 2024, and $2,212,261 as of March 31, 2024.
• The company's auditor has expressed 'substantial doubt about its ability to continue as a going concern' due to these working capital deficits.
• Ms. Kit Wong, the CEO, Director, and Chairman, will retain significant control, holding 91.65% of the total voting power post-IPO (assuming no over-allotment option exercise).
• The company is subject to various risks related to operating in Hong Kong, including potential intervention by the PRC government and uncertainties regarding the application and interpretation of PRC laws and regulations.
• Charming Medical is an 'emerging growth company' and 'foreign private issuer,' allowing it to follow reduced public company reporting and corporate governance requirements.

Sentiment

Score: 5

Explanation: While the company shows strong revenue and net income growth in recent periods, the auditor's 'going concern' warning due to working capital deficits and the extensive list of regulatory and operational risks related to its Hong Kong/PRC context introduce significant uncertainty. The IPO is crucial for addressing liquidity and funding growth, but the overall financial health and external environment present notable challenges.

Positives

• Achieved significant revenue growth of 70.4% in FY2024, reaching $6,015,375, and a 12.0% increase for the six months ended September 30, 2024, reaching $2,958,508.
• Transitioned from a net loss of $335,605 in FY2023 to a net income of $821,743 in FY2024, and maintained profitability in interim periods ($468,817 net income for six months ended September 30, 2024).
• Boasts a professional team of TCM practitioners and skilled technicians, with TCM practitioners holding Registered Chinese Medicine Practitioner Certificates.
• Offers comprehensive one-stop health and wellness services, including feminine care, prenatal/postpartum therapies, and male hair care, with home services introduced during the COVID-19 pandemic.
• Implements high-quality assurance measures for products and services, including contracting with GMP and ISO 9001 certified suppliers.
• Integrates TCM principles with modern technology, such as needle-free thread embedding and TCM E-plus eye care therapy.
• Has an experienced management team with substantial industry expertise.
• Maintains a customer-centric approach, providing personalized services and actively seeking feedback to improve offerings.
• Benefits from Hong Kong government support for TCM wellness, including initiatives to integrate TCM into tourism and wellness centers.
• Observes a rising consumer preference for natural, holistic health solutions and increased awareness of women's health, driving demand for TCM services.
• Has a diversified supply chain with no single supplier accounting for more than 10% of total procurement, ensuring stability and flexibility.
• No single customer accounts for more than 10% of total revenue, reducing customer concentration risk.
• Currently not a party to any material legal or administrative proceedings.
• The Controlling Shareholder, Ms. Kit Wong, has pledged to provide continuous financial support to the company for at least the next 12 months.

Negatives

• The company has a significant working capital deficit of $2,281,970 as of September 30, 2024, and $2,212,261 as of March 31, 2024.
• The auditor has expressed 'substantial doubt about the company's ability to continue as a going concern' due to its working capital deficits.
• The company does not carry product liability insurance or business interruption insurance, exposing it to significant financial risks from claims or disruptions.
• There are no plans to distribute earnings or pay cash dividends in the foreseeable future, meaning investors must rely on share price appreciation for returns.
• The CEO, Kit Wong, holds management positions and directorships in other companies, which could lead to potential conflicts of interest and diversion of time.
• Professional expenses increased significantly by 2,656.6% in FY2024 to $260,224, mainly due to audit fees related to the IPO.
• Staff costs and employee benefits decreased by 2.4% for the six months ended September 30, 2024, partly due to less commissions paid, which could impact employee motivation.
• The company closed a store in Central, Hong Kong in April 2024 as a cost-saving measure, indicating operational adjustments.

Risks

• Uncertainty regarding the interpretation and application of PRC laws and regulations to Hong Kong-based operations, including potential direct oversight and intervention by the PRC government.
• Risk that the PRC government may extend oversight and control over overseas offerings and foreign investment to Hong Kong-based issuers, potentially limiting the company's ability to offer securities or operate.
• Uncertainties as to whether the company will be required to obtain approvals from PRC authorities (e.g., CSRC, CAC cybersecurity review) for its U.S. listing and future operations, with potential sanctions for non-compliance.
• The Hong Kong National Security Law and the U.S. Hong Kong Autonomy Act (HKAA) could impact Hong Kong subsidiaries, potentially affecting business operations and financial position.
• Rapid changes in the enforcement of laws and regulations in Mainland China and Hong Kong could limit legal protections and materially affect operations.
• Political risks associated with conducting business in Hong Kong, including adverse economic, social, and political conditions or social unrest.
• Potential future restrictions by the PRC government on the ability to transfer money out of Hong Kong, distribute earnings, or reinvest in business outside of Hong Kong.
• Compliance with Hong Kong's Personal Data (Privacy) Ordinance (PDPO) entails significant expenses, and any breach could materially affect the business.
• The company operates in a dynamic industry with a limited operating history, meaning historical results may not be indicative of future performance.
• Intense competition in the TCM-inspired wellness and beauty industry could adversely affect market share, revenues, and growth prospects.
• Challenges in building customer trust and boosting customer acceptance due to limited evidence-based validation of TCM and longer timeframes for visible results.
• Significant risks associated with contracting with third-party suppliers, including potential contaminations, defects, or non-compliance with regulations.
• The relative lack of stringent laws and regulations in Hong Kong's wellness and beauty services sector poses a risk of inconsistent service quality and potential adverse effects on reputation if high standards are not maintained.
• Risk of becoming a party to litigation, legal disputes, claims, or administrative proceedings that could materially and adversely affect the company.
• Reliance on the continued and collaborative efforts of senior management and key employees (TCM practitioners, technicians); loss of these personnel could harm the business.
• Failure to obtain and maintain requisite licenses, permits, registrations, and filings, or additional ones required due to new policies or business expansion, could materially and adversely affect operations.
• Inability to protect intellectual property could diminish the value of brands and other intangible assets.
• An economic downturn could adversely affect consumer discretionary spending and demand for the company's products and services.
• Business expansion into other countries will require substantial investment and commitment of resources and is subject to risks and uncertainties.
• Products not having the intended effects or causing undesirable side effects could significantly harm the business, financial condition, and prospects.
• Inherent risks relating to product liability and personal injury claims, exacerbated by the absence of product liability insurance.
• The auditor has expressed substantial doubt about the company's ability to continue as a going concern due to working capital deficits.
• Failure to effectively manage growth could place significant strain on management, personnel, systems, and resources.
• The company's Class A Ordinary Shares may be prohibited from trading on a national exchange under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect its auditors for two consecutive years.
• The stock price may experience extreme volatility unrelated to actual operating performance, making it difficult for investors to assess value.
• The Class A Ordinary Shares may be thinly traded, making it difficult for investors to sell shares at or near ask prices or at all.
• Failure to satisfy or continue to satisfy Nasdaq Capital Market listing requirements could lead to delisting.
• Sales of substantial amounts of Class A Ordinary Shares in the public market after the IPO could adversely affect the market price.
• New investors will experience immediate and substantial dilution in the net tangible book value of Class A Ordinary Shares purchased.
• The company's status as an emerging growth company and foreign private issuer means it will be subject to lessened disclosure requirements and may follow home-country corporate governance practices, potentially affording less protection to shareholders.
• The company has broad discretion in the use of net proceeds from the IPO, and funds may not be used effectively.
• There is no assurance that the company will not be deemed a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. holders.
• Nasdaq may apply additional and more stringent criteria for initial and continued listings due to the relatively small size of the offering and large insider holdings.

Future Outlook

Charming Medical Limited plans to expand its international market share by entering new geographic regions, particularly Southeast Asia, through thorough market research and adapting marketing strategies. The company intends to build strategic partnerships with cosmetic brands, health institutions, and research institutions to foster resource sharing, reduce costs, and drive technological innovation. It will invest in R&D to develop new beauty products and services, including ingredient research for skincare and adopting advanced beauty instruments. The company aims to establish a strong brand image through differentiation, marketing campaigns, quality assurance, and enhanced customer experience, including hosting seminars and workshops. Additionally, it plans to diversify its product and service offerings by expanding TCM-inspired wellness solutions tailored to male consumers.

Management Comments

• "We are committed to enhancing the quality of life from the inside out by integrating TCM wellness practices with modern technology."
• "We believe that our TCM-inspired herbal therapies can help balance the female endocrine system and improve women's constitution and overall health."
• "We intend to meet the cash requirements for the next 12 months from the issuance date of the consolidated financial statements through operations and financial support from our Controlling Shareholder, financial institutions, and investors."
• "We are continuing to focus on improving operational efficiency and cost reductions and enhancing efficiency."
• "We believe our ability to continue as a going concern is not contingent upon obtaining funding from sales of our stock securities in this Offering."
• "We do not believe that any such potential conflicts [from CEO's other roles] would materially affect our ability to conduct our operations."
• "We do not expect to pay cash dividends in the foreseeable future."

Industry Context

The TCM womens wellness and beauty market in Hong Kong is experiencing rapid growth, with the traditional Chinese medicine service market growing from 32.5 billion HKD in 2019 to 36.9 billion HKD in 2023 (CAGR of 3.2%), and projected to reach 57.3 billion HKD by 2030 (CAGR of 6.5%). This growth is driven by increasing health awareness, demand for natural and non-invasive treatments, and government support for TCM. The TCM womens health market, fertility-related TCM services market, and TCM beauty market are all expanding, fueled by factors like rising gynecological issues, delayed childbearing trends, and the influence of social media promoting natural beauty therapies. Wellness centers are evolving into one-stop health service solutions, offering personalized and comprehensive care.

Comparison to Industry Standards

• The document states that the TCM-inspired beauty and wellness industry in Hong Kong and mainland China is subject to significant competition and pricing pressures, with several significant competitors offering products and services at the same or lower prices.
• It highlights that public hospitals typically offer more standardized TCM services at lower costs but with potentially longer waiting times, while private institutions like Charming Medical offer more flexibility and personalized plans at a higher cost.
• The document mentions that industry standards like the Specification of Competency Standards for the Beauty Industry in Hong Kong are voluntary, leading to varying qualifications and service practices across providers, which the company addresses through its own rigorous internal quality control measures and certified practitioners.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceedings.
• The company may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business.

Related Party Transactions

• Amounts due from Ms. Kit Wong (Controlling Shareholder, CEO, Director) for payments made on behalf of the company and receipt of service fees from payment platforms. The balance was US$73,523 as of September 30, 2024, and US$885,056 as of March 31, 2024. These balances were unsecured, interest-free, and had no specific repayment terms. All outstanding balances as of September 30, 2024, and March 31, 2024, have been fully settled or collected as of the prospectus date.
• Staff costs and employee benefits were paid to Ms. Wong Ting Ting (sister of Ms. Wong) and Ms. Liu Qiong (mother of Ms. Wong), both employees of the company. For the six months ended September 30, 2024, these amounted to US$23,091 and US$14,310, respectively. For the fiscal year ended March 31, 2024, these were US$30,674 and US$16,116, respectively.
• Remuneration to senior management (including Ms. Wong) was US$117,518 for the six months ended September 30, 2024, and US$173,034 for the fiscal year ended March 31, 2024.
• Non-cash dividends of HK$4,737,472 (US$605,358) from Pilate and HK$700,918 (US$89,564) from Dream International were declared on March 31, 2024, to Ms. Wong to offset receivable balances owed by her to the company.

Stakeholder Impact

• **Shareholders**: New investors will experience immediate and substantial dilution. The dual-class share structure concentrates voting power with the Controlling Shareholder, potentially limiting minority shareholder influence. There are no anticipated dividends, so returns depend on share price appreciation. Risks related to HFCAA and potential delisting could significantly impact investment value. BVI law offers limited protections compared to U.S. law.
• **Employees**: The company's growth strategies, including international expansion and R&D, could create new opportunities. However, the business relies heavily on retaining key management and skilled TCM practitioners, and competition for talent is intense. Staff costs decreased in the recent interim period due to lower commissions, which could affect employee morale.
• **Customers**: Customers can expect continued and potentially expanded offerings of TCM-inspired beauty and wellness services, with a focus on personalized care and quality assurance. The company aims to enhance customer satisfaction and loyalty through continuous improvement and engagement.
• **Suppliers**: The company maintains a diversified supply chain, which provides stability but also means no single supplier has a dominant position. The company prioritizes suppliers with quality certifications (GMP, ISO 9001).
• **Creditors**: The company's working capital deficit and the auditor's 'going concern' opinion indicate potential challenges in meeting short-term obligations. However, management's plans to secure additional financing and the Controlling Shareholder's pledge of financial support aim to mitigate these risks.

Next Steps

• Complete the Initial Public Offering and listing of Class A Ordinary Shares on the Nasdaq Capital Market.
• Utilize the net proceeds from the offering for business expansion, strategic investments and acquisitions, research and development, and general working capital.
• Continue efforts to improve operational efficiency and reduce costs to address the working capital deficit and going concern issues.
• Monitor and comply with evolving PRC and Hong Kong laws and regulations, particularly those related to data security and overseas listings.
• Maintain the listing of Class A Ordinary Shares on the Nasdaq Capital Market for a period of two years.
• File all required periodic reports with the SEC as a foreign private issuer.

Key Dates

Recommendation

Keywords

Traditional Chinese Medicine, TCM, Wellness, Beauty, Postpartum Services, Hong Kong, IPO, Nasdaq, Healthcare, Supplements, Cosmetics, Personal Care, Health Services, Beauty Lab Group